FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
2022 Q3
2022 Q2
2022 Q1
2021 Q4
1.13M
0
2.55M
17.5M
0
0
0
0
1.13M
0
2.55M
17.5M
14.83M
16.18M
13.74M
13.18M
9.67M
8.72M
8.04M
8.21M
5.16M
7.46M
5.7M
4.96M
0
0
0
0
5.16M
7.46M
5.7M
4.96M
-4.26M
-2.35M
-533k
0
-13.71M
-16.18M
-11.19M
4.18M
-4.7M
-2.81M
-899k
285k
-18.41M
-18.99M
-12.09M
4.18M
60k
127k
58k
-562k
-18.47M
-19.12M
-12.14M
4.74M
-0.84
-0.89
-0.58
0.23
-0.84
-0.89
-0.58
0.23
21.86M
21.57M
21.08M
20.62M
21.86M
21.57M
21.08M
20.62M
-17.78M
-18.38M
-11.53M
3.57M
All figures are in USD.